Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

por Carlos Taxonera, María Pilar Martínez-Montiel, Manuel Barreiro-de-Acosta, Isabel Vera, Rufo Lorente, Pablo Vega, María Teresa Diz-Lois, Ana María Fuentes Coronel, José Lázaro Pérez Calle, Begoña Casis, Rocío Ferreiro-Iglesias, Marta Calvo, David Olivares, Cristina Alba
Publicado 2021

Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved

por Luis G. Guijarro, David Cano-Martínez, M.Val Toledo-Lobo, Patricia Sanmartín Salinas, María Chaparro, Ana M. Gómez-Lahoz, Sofía Zoullas, Rosa Rodríguez-Torres, Irene D. Román, Laura Sebastián Monasor, Lidia Ruiz-Llorente, María del Carmen Boyano-Adánez, Iván Guerra, Marisa Iborra, José Luis Cabriada, Luis Bujanda, Carlos Taxonera, Valle García-Sánchez, Ignacio Marín-Jiménez, Manuel Barreiro-de Acosta, Isabel Vera, María Dolores Martín-Arranz, Francisco Mesonero, Laura Sempere, Fernando Gomollón, Joaquín Hinojosa, Melchor Alvarez-Mon, Javier P. Gisbert, Miguel A. Ortega, Borja Hernández-Breijo, on behalf of the PREDICROHN study group from GETECCU
Publicado 2021